CD19 and B-cell chronic lymphocytic leukemia: CD19-targeted CAR constructs have been used widely and demonstrate consistently high antitumor activity in patients with relapsed B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and B-cell non-Hodgkin lymphoma.